Health
-
Milan, Italy, July 08 — Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has today announced the publication of preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat methylmalonic acidemia (MMA), a severe inherited metabolic disorder. The findings, published in the Journal of Hepatology, show that a single systemic administration of a lentiviral vector encoding the MMUT gene led to sustained improvements in disease features in a validated mouse model of MMA, with effects lasting for the average lifespan of laboratory mice. Since the mice were treated when young, the study supports the durability of the gene therapy through postnatal growth and maturation of the liver. MMA is caused by a deficiency of methylmalonyl-CoA mutase, an enzyme that plays a critical role in the body’s metabolism of food. Its absence results in the accumulation of toxic metabolites that lead to recurrent metabolic crises, growth failure, neurological impairment,…
-
Rourkela, July 8 (UDN): Researchers at NIT Rourkela have developed a smart bandage that could…
-
Bhopal, July 8: The Madhya Pradesh Government is working to expand digital healthcare services to…
-
Lucknow, July 8: The Uttar Pradesh government has launched a new cashless healthcare scheme aimed…
-
New Delhi, July 8: The Government has approved Navi Mumbai International Airport as an authorised…
-
Gandhinagar, July 7: Health facilities across Gujarat have removed more than five lakh unused and…
-
July 6: The Ayushman Bharat Digital Mission (ABDM) has achieved a major milestone by linking over…
-
Hyderabad, July 6: A significant milestone in healthcare was marked today with the grand…
-
Baripada, July 4 (UDN): Around 20 students of Kasturba Gandhi Balika Vidyalaya (KGBV) at Chandua…
-
July 3 (UDN):A 10-month-old baby boy died at Kujanga Community Health Centre (CHC) in Odisha’s…